Home
Productsindex
Gene
mRNA Productsindex
mRNAs for Replacement Therapy Developmentlists
Interferon-β1a  In Vitro Transcribed mRNA-LNP
SG-MRNA-LNP-1887
Interferon-β1a In Vitro Transcribed mRNA-LNP
Source:The ORF of Interferon-β1a was cloned in our IVT vector and mRNA was prepared through in vitro transcription and purification. The purified mRNA was further encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102).
Alternative Names:Interferon-β1a
SKU:SG-MRNA-LNP-1887-DCPS
Product Name:Interferon-β1a In Vitro Transcribed mRNA-LNP(DSPC:Cholesterol:DMG-PEG:SM102)
Product Description:Interferon-β1a In Vitro Transcribed mRNA encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102)
SKU:SG-MRNA-LNP-1887-DCPS
Product Name:Interferon-β1a In Vitro Transcribed mRNA-LNP(DSPC:Cholesterol:DMG-PEG:SM102)
Product Description:Interferon-β1a In Vitro Transcribed mRNA encapsulated with LNP(DSPC:Cholesterol:DMG-PEG:SM102)
PROPERTIES
Cap:
m7GpppN
5'-UTR:
5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF:
Interferon-β1a
3'-UTR:
3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail:
A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another 70 adenosine residues.
Modifications:
N1-methyl-pseudouridine
Neutral Lipid:
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol:
Cholesterol
Lonizable Lipid:
1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid:
Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)− 8-oxooctyl)amino)octanoate)(SM-102)
Storage:
-20 °C
Buffer:
PBS, pH7.4
Cryoprotectant:
Trehalose
Background

Gene Alias

Interferon-β1a

Background

Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses. Interferon beta has not been shown to slow the advance of disability. Interferons are not a cure for MS (there is no known cure); the claim is that interferons may slow the progress of the disease if started early and continued for the duration of the disease.

RECOMMENDED PRODUCTS
BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
ABL1

SGRP00624

BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
ABL1

SGRP00628

BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
AKT1

SGRP00630

BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
AKT1

SGRP00631

BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
ALK

SGRP00637

BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
View Price and Availability
0.118241s